Noteworthy ETF Inflows: DFAC, CVX, WFC, MRK
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 28 2025
0mins
Source: NASDAQ.COM
DFAC Stock Performance: DFAC's stock has a 52-week range with a low of $28.39 and a high of $36.66, currently trading at $34.37, which is useful for technical analysis when compared to the 200-day moving average.
ETFs Trading Dynamics: Exchange traded funds (ETFs) operate like stocks but involve buying and selling units that can be created or destroyed based on investor demand, impacting the underlying holdings significantly during notable inflows or outflows.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRK
Wall Street analysts forecast MRK stock price to fall
16 Analyst Rating
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 125.370
Low
95.00
Averages
119.53
High
139.00
Current: 125.370
Low
95.00
Averages
119.53
High
139.00
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Schwab U.S. Dividend ETF Shows Strong Performance
- CAGR Performance: The Schwab U.S. Dividend ETF has achieved a compound annual growth rate (CAGR) of 13.3% since its inception in 2011, indicating strong performance despite not being available for a full 15 years.
- Dividend Contribution: Approximately 38% of the ETF's total returns come from dividends, highlighting their significance in investment returns; without dividends, an initial $10,000 investment would only be worth about $38,000 today.
- Portfolio Diversity: The ETF currently holds 103 stocks, primarily investing in financially sound U.S. companies that consistently pay dividends, such as Merck, Home Depot, and Coca-Cola, ensuring stability and profitability in its investments.
- Market Comparison: While the Schwab ETF has performed well, an investment of $10,000 in the S&P 500 index fund on October 20, 2011, would have grown to approximately $79,700, illustrating the competitive nature of the market.
See More
The Potential and Returns of Dividend Investing
- Significant Investment Returns: An investment of $10,000 in the Schwab U.S. Dividend Equity ETF 15 years ago would be worth approximately $61,200 today, showcasing the fund's strong performance and appeal.
- Compound Annual Growth Rate: The ETF has achieved a compound annual growth rate of 13.3% since its inception, with an impressive 29% growth rate over the past 12 months, indicating its competitive edge and investment value in the market.
- Importance of Dividends: Dividends accounted for about 38% of total returns since 2011; without them, a $10,000 investment would only be worth $38,000, highlighting the critical role dividends play in investment returns.
- Comparison with S&P 500: While the Schwab ETF has performed well, it still lags behind the Vanguard 500 Index Fund, which would have turned a $10,000 investment into approximately $79,700 during the same period, illustrating the diversity of market options and the importance of selection.
See More
Moderna's Expanding Pipeline Sparks Investor Interest
- Product Line Expansion: Moderna's stock has surged nearly 150% over the past year, making it one of the best performers in the S&P 500, reflecting strong market confidence in its new product lines, although it remains below the pandemic peak of $484 in 2021.
- Cancer Treatment Progress: The company's efforts in cancer therapies have garnered investor attention, with mid and late-stage trials targeting melanoma and non-small cell lung cancer underway, with significant study results expected later this year that could drive new growth.
- Vaccine Development Advances: Moderna's experimental flu vaccine received a recommendation from the FDA advisory committee, with a regulatory decision expected on August 5, while its combination Covid and flu vaccine has been approved by the European Commission, enhancing the diversity of its product portfolio.
- Future Outlook: Cramer highlighted that Moderna has presented a clear roadmap to profitability for the first time, emphasizing its potential in cancer and vaccine sectors, and while it may take years to realize, the company's future outlook remains optimistic, advising investors to wait for the right buying opportunity.
See More
Merck Halts Alzheimer’s Drug Trial MK-1167 Due to Poor Performance
- Trial Termination Reason: Merck decided to halt the mid-stage study of MK-1167 after an early planned review indicated the drug did not meet performance standards for continuation, although no safety concerns were identified, highlighting the drug's ineffectiveness in improving memory and cognition in Alzheimer's patients.
- Market Reaction: Following the trial termination, Merck's shares fell over 2%, while its partner Neuphoria Therapeutics saw a 19% drop in stock price, reflecting investor disappointment and underscoring the market's keen interest in Alzheimer's treatment developments.
- Ongoing Research: Despite the halt of MK-1167, Merck remains active in Alzheimer's research, continuing to test another experimental drug, MK-2214, with results expected in 2029, indicating the company's long-term commitment to this therapeutic area.
- Analyst Ratings: According to Koyfn data, 19 out of 29 analysts covering Merck rated it as 'Buy' or 'Strong Buy', demonstrating confidence in the company's future potential, despite short-term stock price fluctuations due to trial results.
See More
Merck Halts Development of Alzheimer's Drug MK-1167
- Development Halted: Merck has terminated the development of MK-1167, an oral positive allosteric modulator of the alpha-7 nicotinic acetylcholine receptor, in phase 2 for Alzheimer's disease, citing business reasons, indicating a strategic shift in the company's approach to Alzheimer's treatment.
- Partnership Impact: The asset was developed in collaboration with Neuphoria Therapeutics under a licensing agreement, and the termination may affect future collaborations and resource allocation between the two companies, highlighting the fragility of partnerships in the pharmaceutical industry.
- Ongoing Research: Despite the halt of MK-1167, Merck continues to advance MK-2214, an antibody targeting phosphorylated serine 413 (pS413) tau in phase 2 trials, suggesting that the company still has other potential treatment options in the Alzheimer's space.
- Market Reaction: Following the announcement, Merck's stock declined, ending a six-day rally, reflecting investor uncertainty regarding the company's research direction and concerns about future profitability.
See More
DFUS Stock Price Analysis and ETF Dynamics
- Price Fluctuation Analysis: DFUS's 52-week low is $66.95 and high is $82.965, with the latest trade at $81.95, indicating price volatility near the high point that may influence investor buying decisions.
- Technical Analysis Tool: Comparing the latest stock price to the 200-day moving average can provide valuable insights for investors, helping to assess price trends and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding helps identify those experiencing significant inflows (new units created) or outflows (old units destroyed), assessing their impact on underlying holdings.
See More
Schwab U.S. Dividend ETF Shows Strong Performance
- CAGR Performance: The Schwab U.S. Dividend ETF has achieved a compound annual growth rate (CAGR) of 13.3% since its inception in 2011, indicating strong performance despite not being available for a full 15 years.
- Dividend Contribution: Approximately 38% of the ETF's total returns come from dividends, highlighting their significance in investment returns; without dividends, an initial $10,000 investment would only be worth about $38,000 today.
- Portfolio Diversity: The ETF currently holds 103 stocks, primarily investing in financially sound U.S. companies that consistently pay dividends, such as Merck, Home Depot, and Coca-Cola, ensuring stability and profitability in its investments.
- Market Comparison: While the Schwab ETF has performed well, an investment of $10,000 in the S&P 500 index fund on October 20, 2011, would have grown to approximately $79,700, illustrating the competitive nature of the market.
See More
The Potential and Returns of Dividend Investing
- Significant Investment Returns: An investment of $10,000 in the Schwab U.S. Dividend Equity ETF 15 years ago would be worth approximately $61,200 today, showcasing the fund's strong performance and appeal.
- Compound Annual Growth Rate: The ETF has achieved a compound annual growth rate of 13.3% since its inception, with an impressive 29% growth rate over the past 12 months, indicating its competitive edge and investment value in the market.
- Importance of Dividends: Dividends accounted for about 38% of total returns since 2011; without them, a $10,000 investment would only be worth $38,000, highlighting the critical role dividends play in investment returns.
- Comparison with S&P 500: While the Schwab ETF has performed well, it still lags behind the Vanguard 500 Index Fund, which would have turned a $10,000 investment into approximately $79,700 during the same period, illustrating the diversity of market options and the importance of selection.
See More
Moderna's Expanding Pipeline Sparks Investor Interest
- Product Line Expansion: Moderna's stock has surged nearly 150% over the past year, making it one of the best performers in the S&P 500, reflecting strong market confidence in its new product lines, although it remains below the pandemic peak of $484 in 2021.
- Cancer Treatment Progress: The company's efforts in cancer therapies have garnered investor attention, with mid and late-stage trials targeting melanoma and non-small cell lung cancer underway, with significant study results expected later this year that could drive new growth.
- Vaccine Development Advances: Moderna's experimental flu vaccine received a recommendation from the FDA advisory committee, with a regulatory decision expected on August 5, while its combination Covid and flu vaccine has been approved by the European Commission, enhancing the diversity of its product portfolio.
- Future Outlook: Cramer highlighted that Moderna has presented a clear roadmap to profitability for the first time, emphasizing its potential in cancer and vaccine sectors, and while it may take years to realize, the company's future outlook remains optimistic, advising investors to wait for the right buying opportunity.
See More
Merck Halts Alzheimer’s Drug Trial MK-1167 Due to Poor Performance
- Trial Termination Reason: Merck decided to halt the mid-stage study of MK-1167 after an early planned review indicated the drug did not meet performance standards for continuation, although no safety concerns were identified, highlighting the drug's ineffectiveness in improving memory and cognition in Alzheimer's patients.
- Market Reaction: Following the trial termination, Merck's shares fell over 2%, while its partner Neuphoria Therapeutics saw a 19% drop in stock price, reflecting investor disappointment and underscoring the market's keen interest in Alzheimer's treatment developments.
- Ongoing Research: Despite the halt of MK-1167, Merck remains active in Alzheimer's research, continuing to test another experimental drug, MK-2214, with results expected in 2029, indicating the company's long-term commitment to this therapeutic area.
- Analyst Ratings: According to Koyfn data, 19 out of 29 analysts covering Merck rated it as 'Buy' or 'Strong Buy', demonstrating confidence in the company's future potential, despite short-term stock price fluctuations due to trial results.
See More
Merck Halts Development of Alzheimer's Drug MK-1167
- Development Halted: Merck has terminated the development of MK-1167, an oral positive allosteric modulator of the alpha-7 nicotinic acetylcholine receptor, in phase 2 for Alzheimer's disease, citing business reasons, indicating a strategic shift in the company's approach to Alzheimer's treatment.
- Partnership Impact: The asset was developed in collaboration with Neuphoria Therapeutics under a licensing agreement, and the termination may affect future collaborations and resource allocation between the two companies, highlighting the fragility of partnerships in the pharmaceutical industry.
- Ongoing Research: Despite the halt of MK-1167, Merck continues to advance MK-2214, an antibody targeting phosphorylated serine 413 (pS413) tau in phase 2 trials, suggesting that the company still has other potential treatment options in the Alzheimer's space.
- Market Reaction: Following the announcement, Merck's stock declined, ending a six-day rally, reflecting investor uncertainty regarding the company's research direction and concerns about future profitability.
See More
DFUS Stock Price Analysis and ETF Dynamics
- Price Fluctuation Analysis: DFUS's 52-week low is $66.95 and high is $82.965, with the latest trade at $81.95, indicating price volatility near the high point that may influence investor buying decisions.
- Technical Analysis Tool: Comparing the latest stock price to the 200-day moving average can provide valuable insights for investors, helping to assess price trends and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding helps identify those experiencing significant inflows (new units created) or outflows (old units destroyed), assessing their impact on underlying holdings.
See More
